Short-term sPECAM-Fc treatment ameliorates EAE while chronic use hastens onset of symptoms

Emily K. Reinke, JangEun Lee, Alla Zozulya, Jozsef Karman, William A. Muller, Matyas Sandor, Zsuzsanna Fabry*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


The homophilic cell adhesion molecule PECAM-1 is a major participant in the migration of leukocytes across endothelium. We examined the ability of a chimeric soluble PECAM-1 fused to human IgG-Fc to impair leukocyte entry through the blood-brain barrier and reduce CNS autoimmunity. sPECAM-Fc impaired migration of lymphocytes across brain endothelial monolayers and diminished the severity of EAE, an experimental model of MS, when administered at the onset of symptoms. However, in mice transgenic for sPECAM-Fc, the chronically elevated levels of sPECAM-Fc hastened onset of EAE disease without significantly changing clinical score severity. Our data suggest that short-term treatment of diseases like MS with sPECAM-Fc has therapeutic potential.

Original languageEnglish (US)
Pages (from-to)86-93
Number of pages8
JournalJournal of Neuroimmunology
Issue number1-2
StatePublished - May 2007


  • Cellular migration
  • EAE
  • MS
  • PECAM-1
  • sPECAM-Fc

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Short-term sPECAM-Fc treatment ameliorates EAE while chronic use hastens onset of symptoms'. Together they form a unique fingerprint.

Cite this